PPMA warns any decision to stop import of Indian drug raw material will weaken Pakistan’s ability to fight Covid-19


By Abdul Rafay Siddiqi

KARACHI: The Pakistan Pharmaceutical Manufacturers’ Association (PPMA) has warned the federal government that any decision to discontinue import of raw material of medicines from India will weaken the country’s ability to fight the coronavirus.

The warning to this effect came as the office-bearers of PPMA addressed a press conference here at Press Club yesterday. The PPMA representatives appealed to the federal government that it should continue with the existing arrangements of import of drugs’ raw material. Any decision to disrupt the international supply chains associated with the Pakistani pharmaceutical industry will lessen the ability of the country’s medical practitioners to treat the cases of Covid-19.

“We are in a virtual state of war against Covid-19 whose cases have been on the rise in Pakistan as the pharmaceutical industry is the backbone of the national apparatus put in place to fight the menace of coronavirus,” he said.

He said that the vital inputs of the pharmaceutical industry should remain readily available to the drug manufacturers so that there was no shortage of essential medicines in the country during the current health emergency.

“From the day one of the anti-coronavirus lockdown in the country the pharmaceutical industry has been doing its best continue with its production so that there is no shortage of medicines during the on-going health crisis,” he said.


Please enter your comment!
Please enter your name here